The area under the curve (AUC) of IL-6 and IL-17A in the diagnosis of prostate cancer patients were 0.721, and 0.710, respectively, demonstrates “good” capability for discriminating between patients with PCa and controls. Here, IL17A is linked to posterior cortical atrophy.